Program planning and continual evaluation have been critical for the development of the Cancer Therapy & Research Center (CTRC) and its research infrastructure. CTRC uses both internal and external sources for review and evaluation, soliciting input from Cancer Center experts. The CTRC External Advisory Board is the primary external mechanism for review and advice on the CTRC and its progress in both clinical and basic research. CTRC has also utilized smaller ad hoc advisory groups for Cancer Center Administration, Shared Resources and Programs. Internal mechanisms for planning and evaluation center around the CTRC Executive Committee (EC), which includes the CTRC Associate Directors and Program Leaders, as well as the CTRC Internal Advisory Board (lAB) and the CTRC Shared Resources Oversight Committee. The lAB includes Senior Leaders from the University of Texas Health Science Center (UTHSCSA), who meet annually to provide feedback on CTRC's progress in clinical and research arenas at the UTHSCSA. The Shared Resources Oversight Committee aids the Center through annual evaluation of the CTRC Shared Resources as well as by making recommendations with respect to CTRC Shared Resources. ! A key part of the CTRC planning and evaluation process has been the development of a CTRC Strategic Plan. A number of groups including those mentioned above have had a role in the strategic planning process. The CTRC Strategic Plan was developed and organized in accordance with the Six Essential Characteristics of NCI-Designated Cancer Centers. A critical element of the CTRC Strategic Plan is the renewed focus of the CTRC on serving its catchment area and understanding cancer in our predominantly Hispanic population. Other areas of focus include expansion of team science in the CTRC, outreach to other institutions of higher education in the area, and targeted recruitment of faculty to build the clinical and research enterprise of the CTRC.

Public Health Relevance

The continuously ongoing planning and evaluation processes of the CTRC have been a critical component of the rebuilding that has occurred over the past funding period. A sustained focus on the CTRC Strategic Plan will be key to its growth and success.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-20
Application #
8758434
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Project Start
1997-08-01
Project End
2019-07-31
Budget Start
2014-09-16
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$56,779
Indirect Cost
$39,732
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Zanotto-Filho, Alfeu; Dashnamoorthy, Ravi; Loranc, Eva et al. (2016) Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One 11:e0153970
Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20
Ortiz, Carmen; Morales, Luisa; Sastre, Miguel et al. (2016) Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A. Evid Based Complement Alternat Med 2016:3696232
Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40
Zanotto-Filho, Alfeu; Masamsetti, V Pragathi; Loranc, Eva et al. (2016) Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther 15:3000-3014
Sareddy, Gangadhara R; Li, Xiaonan; Liu, Jinyou et al. (2016) Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6:24185
Sweeney, Shannon R; Kavanaugh, Arthur; Lodi, Alessia et al. (2016) Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open 2:e000289
Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82
Toledo, Rodrigo A; Qin, Yuejuan; Cheng, Zi-Ming et al. (2016) Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res 22:2301-10
Wu, Anqi; Dong, Qiaoxiang; Gao, Hui et al. (2016) Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets. Sci Rep 6:32190

Showing the most recent 10 out of 853 publications